Corporate Profile

AT A GLANCE

Chairman of the Board and CEO	Robert J. Coury
Vice Chairman	Rodney L. Piatt
Corporate headquarters	Pittsburgh, Pa., U.S.
Founded	1961, White Sulphur Springs, W.Va., U.S.
Employees	Approximately 15,000
2008 revenue (USD)	5.14 billion
Product portfolio	More than 900 separate products
Commercial footprint	More than 140 countries and territories
Manufacturing capacity	Approximately 45 billion doses
Memberships	Fortune 500, S&P 500
Stock exchange listing	Nasdaq: MYL
Pronunciation	Mylan [mī-luhn]

PRIMARY BUSINESSES AND OPERATIONS

Generic pharmaceuticals and branded Generics
Specialty and brand pharmaceuticals
Active pharmaceutical ingredients

MYLAN’S GLOBAL OPERATIONS

North America
EMEA
APAC
Specialty
Matrix
Other

» North America

Already the second largest generic pharmaceutical company in the U.S., Mylan continues to expand its presence in that market, the world's largest. Mylan also has a significant and well-established presence in the Canadian pharmaceutical market. The company's North American businesses include Mylan Pharmaceuticals, Genpharm ULC, Mylan Technologies and UDL Laboratories.

» EMEA

Mylan operates throughout Europe, the Middle East and Africa (EMEA), with manufacturing, packaging, distribution and marketing capabilities throughout the region. These businesses presently hold top-five positions in several markets, including No. 1 positions in France and Portugal. Mylan also has a strong presence – and significant opportunities for growth – in Spain, Italy, Portugal, Belgium, the Netherlands, Scandinavia and Ireland.

Mylan EMEA businesses include those that operate under the Mylan name in Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, the Netherlands, Norway, Poland, Portugal, Scandinavia, Slovakia, Slovenia, Spain, Sweden, Switzerland and South Africa. Our other EMEA businesses include Arcana Arzneimittel, Generics [UK] Limited, Generics Pharma Hellas, Gerard Laboratories and Qualimed. Docpharma distributes generic pharmaceuticals in Belgium, the Netherlands and Luxembourg.

» APAC

Mylan’s Asia-Pacific (APAC) presence includes market-leading positions in Australia and New Zealand, as well as a growing presence in Japan, the world’s second largest pharmaceutical market. Mylan maintains a full complement of capabilities in the region, from product development and manufacturing, to marketing and distribution of both prescription and over-the-counter medicines. Mylan's Asia-Pacific businesses include Alphapharm, Mylan Seiyaku and Mylan New Zealand.

» Specialty

A proven leader in traditional generic pharmaceuticals, Mylan also operates Dey, a specialty business focused on respiratory and allergy therapies.

» Matrix

Matrix is the world's third largest supplier of active pharmaceutical ingredients (API) and intermediates. Based in Hyderabad, India, Matrix has several operating units, including a network of API manufacturing facilities across India and China. Its subsidiaries include Concord Biotech Limited, Explora Laboratories SA, Matrix Laboratories N.V. and Matrix Pharma Group (Xiamen) Limited. Matrix also owns and operates Docpharma, a distributor of generic pharmaceuticals in Belgium, the Netherlands and Luxembourg. In addition, Matrix is a major supplier of API and finished dosage forms of antiretroviral products, which are used to treat people living with HIV/AIDS.

» Other

Mylan also owns Somerset Pharmaceuticals Inc., a proprietary research and development company located in Tampa, Fla. Somerset developed EMSAM^®, a transdermal patch for the treatment of major depressive disorder, currently manufactured by Mylan Technologies and marketed in the U.S. by Dey.